Statins Enhance the Molecular Response in Chronic Myeloid Leukemia when Combined with Tyrosine Kinase Inhibitors.

Cancers (Basel) · 2021 · PMC8582667 · PMID 34771705

Europe PMC DOI

hedged sentence

0.0730

closest p · 1.5× alpha

0.0730

boldest claim

The sentences

showed a trendp = 0.073so close (0.05 < p ≤ 0.1)

In addition, the statin group showed a trend of higher MMR rates compared to the non-statin group ( p = 0.073) (78.8% vs. 62.6% for MMR at 3 years).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.